Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051934 | 0.87 | HTR1A (0.43) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31051978 | 0.84 | ADRB1 (0.55) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31052231 | 0.80 | DRD2 (0.49) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31052184 | 0.79 | DRD2 (0.55) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31051911 | 0.79 | DRD2 (0.48) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31052148 | 0.79 | HTR1A (0.52) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31052202 | 0.76 | ADRB1 (0.37) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL31051908 | 0.72 | HTR1A (0.43) | DRD2HTR1A | |
| SCHEMBL31051899 | 0.72 | HTR1A (0.43) | DRD2HTR1A | |
| SCHEMBL13499602 | 0.72 | ADRB1 (0.67) | DRD2HTR1ADRD3DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |